Aegerion Pharmaceuticals, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2005-01-01
- Employees
- 236
- Market Cap
- -
- Website
- http://www.aegerion.com
Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) Inhibitor
- First Posted Date
- 2012-03-19
- Last Posted Date
- 2013-04-10
- Lead Sponsor
- Aegerion Pharmaceuticals, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT01556906
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia
- First Posted Date
- 2009-07-22
- Last Posted Date
- 2018-06-13
- Lead Sponsor
- Aegerion Pharmaceuticals, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT00943306
- Locations
- 🇨🇦
Robarts Research Institute, London, Ontario, Canada
🇨🇦Lipid Clinic and University of Montreal Community Genomic Medicine Center, Chicoutimi, Quebec, Canada
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)
- First Posted Date
- 2008-08-08
- Last Posted Date
- 2018-03-20
- Lead Sponsor
- Aegerion Pharmaceuticals, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT00730236
- Locations
- 🇮🇹
Dipartimento di Medicina Clinica e Della Patalogie Emergenti, Palermo, Sicily, Italy
🇨🇦Robarts Research Institute, London, Ontario, Canada
🇮🇹Centro Universitario Dislipidemie, Milano, Italy
Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia
- First Posted Date
- 2008-06-04
- Last Posted Date
- 2018-02-23
- Lead Sponsor
- Aegerion Pharmaceuticals, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT00690443
- Locations
- 🇺🇸
Michele Reynolds, MD, Dallas, Texas, United States
🇺🇸Linda Murray, DO - Radiant Research, Pinellas Park, Florida, United States
🇺🇸Dennis McCluskey, MD - Radiant Research, Mogadore, Ohio, United States
Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS
- Conditions
- Interventions
- First Posted Date
- 2007-11-19
- Last Posted Date
- 2018-02-23
- Lead Sponsor
- Aegerion Pharmaceuticals, Inc.
- Target Recruit Count
- 260
- Registration Number
- NCT00559962
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸Scripps Clinic, San Diego, California, United States
🇺🇸MedStar Research Institute, Washington, District of Columbia, United States
AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia
- First Posted Date
- 2007-05-16
- Last Posted Date
- 2018-03-20
- Lead Sponsor
- Aegerion Pharmaceuticals, Inc.
- Target Recruit Count
- 157
- Registration Number
- NCT00474240
- Locations
- 🇺🇸
Sterling Research Group, Cincinnati, Ohio, United States
🇺🇸National Clinical Research, Richmond, Virginia, United States
🇺🇸Coastal Carolina Research Center, Goose Creek, South Carolina, United States
The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia
- Conditions
- First Posted Date
- 2006-11-29
- Last Posted Date
- 2014-03-04
- Lead Sponsor
- Aegerion Pharmaceuticals, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00405067
- Locations
- 🇺🇸
Pharmanet, Inc, Princeton, New Jersey, United States
Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents
- Conditions
- First Posted Date
- 2006-08-02
- Last Posted Date
- 2018-02-23
- Lead Sponsor
- Aegerion Pharmaceuticals, Inc.
- Target Recruit Count
- 125
- Registration Number
- NCT00359281
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States